The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation

See more here:
22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and...

Nicosia, Cyprus, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich (http://www.slavich.ru), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma (http://kraspharma.ru) and Bebig (http://en.bebig.ru/) being added in due course.

Read more from the original source:
Rafarma Closes Biocogency Merger

DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of Nephrology (ASN) Kidney Week 2020, which is being held virtually from October 22-25, 2020. The abstracts will highlight clinical and nonclinical data from novel drug formulations being developed for the treatment of chronic kidney disease (CKD), acute kidney injury (AKI), and COVID-19.

Read the original post:
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice

See the article here:
Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR...

MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial Results on Monday, November 2, 2020, at 4:30pm Eastern Time.

More here:
Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call

Daix (France), October 19, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to odiparcil, the Company’s clinical-stage drug candidate for the treatment of MPS type VI (MPS VI), a rare and progressive genetic disorder.

See more here:
Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7374769.

Link:
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION 19 OCTOBER 2020 at 20.35 EEST

The rest is here:
Orion upgrades full-year outlook for 2020

EMERYVILLE, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be report financial results for the third quarter 2020 after market close on Thursday, November 12, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

See more here:
Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release third quarter 2020 financial and operating results after market close on Monday, November 2, 2020. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

Read the rest here:
Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2

Originally posted here:
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.

Read the original post:
Replimune Appoints Tanya Lewis to the Board of Directors

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

View post:
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

Originally posted here:
Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board

Continued here:
Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Go here to see the original:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

Originally posted here:
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a registered direct offering of 833,333 shares of common stock at a price to the public of $6.00 per share.  The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

Link:
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.

Continued here:
Theratechnologies Appoints Two New Board Members

MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.

See the original post here:
Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen